½ÃÀ庸°í¼­
»óǰÄÚµå
1609137

¼¼°èÀÇ ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå : À¯Çüº°, Ä¡·áÁ¦ À¯Çüº° ¿¹Ãø(2025-2030³â)

Narcolepsy Drugs Market by Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy), Therapeutics Type (Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 196 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

±â¸éÁõ Ä¡·áÀç ½ÃÀåÀº 2023³â 30¾ï 5,000¸¸ ´Þ·¯, 2024³â 32¾ï 8,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 6.77%·Î ¼ºÀåÇØ 2030³â¿¡´Â 48¾ï 3,000¸¸ ´Þ·¯°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â¸éÁõ Ä¡·áÁ¦´Â ¼ö¸é °¢¼º »çÀÌŬÀ» Á¶ÀýÇÒ ¼ö ¾øÀ¸¸ç ³· µ¿¾È °úµµÇÑ Á¹À½, īŸÇ÷º½Ã, ¾ß°£ ¼ö¸éÀå¾Ö µîÀ» ÀÏÀ¸Å°´Â ¸¸¼º ½Å°æ Áúȯ¿¡ ´ëÇÑ Ç¥Àû Ä¡·áÁ¦ÀÔ´Ï´Ù. ¾à¹°ÀÇ Çʿ伺Àº ±â¸éÁõÀÌ »îÀÇ Áú¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í È¿°úÀûÀÎ °ü¸® Àü·«ÀÌ ÇÊ¿äÇ߱⠶§¹®ÀÔ´Ï´Ù. ÀÚ±ØÁ¦, īŸÇ÷º½Ã¸¦ Á¦¾îÇÏ´Â Ç׿ì¿ïÁ¦, ¿©·¯ Áõ»ó¿¡ ´ëóÇÏ´Â ¿Á½Ãº£ÀÌÆ® ³ªÆ®·ý µîÀÌ ÀÖ½À´Ï´Ù. ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Áø´Ü »ç·Ê Áõ°¡, ¾à¹° Àü´ÞÀ» °³¼±ÇÏ´Â ±â¼úÀÇ Áøº¸, ÀÇ·áºñ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.ºÎÀÛ¿ëÀÌ ÀûÀº ½Å±Ô Ä¡·á¹ýÀÇ °³¹ßÀÌ ÃßÁøµÇ°í ÀÖ¾î, ¸ÂÃãÇü ÀǷᳪ ¹ÙÀÌ¿À Å×Å©³î·ÎÁö¿¡ ÀÇÇÑ Çõ½Å¿¡ ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ°¡ ÆÛÁö°í ÀÖ½À´Ï´Ù. ¿¬±¸¿¡¼­ ÀΰøÁö´ÉÀÇ ÅëÇÕÀº ½ÃÀå »óȲÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ¹Ì°³¹ß Áö¿ªÀÇ ÀÎÁöµµ°¡ ³·°í »õ·Î¿î Ä¡·á¹ýÀÇ µµÀÔÀ» ´ÊÃß´Â ¾ö°ÝÇÑ ±ÔÁ¦»óÀÇ Àå¾Ö¹° µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ·çÄÚ·¾½ÃÀÇ À¯ÀüÀû ¼ÒÀÎÀ» ¹àÈ÷±â À§ÇÑ Á¶»ç ¿¬±¸´Â °³Ã´ÀÇ ¿©Áö°¡ ÀÖ½À´Ï´Ù.½ÃÀåÀº ¿ªµ¿ÀûÀÌ¸ç ±Þ¼ÓÇÑ °úÇÐ ¹ßÀü°ú ¼ÒºñÀÚ ÀÇ½Ä º¯È­¿¡ ÀûÀÀÇØ¾ßÇϹǷΠÀÌÇØ °ü°èÀÚ´Â Ç×»ó ¹ÎøÇÏ°Ô Á¤º¸¸¦ ¼öÁýÇØ¾ßÇÕ´Ï´Ù. ´ëóÇÔÀ¸·Î½á ºÎ´ãÀÌ Å« °æ·Î¸¦ ÃÖÀûÈ­Çϰí Á¦Ç°¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÌ°í º¸´Ù ³Î¸® ¹Þ¾Æµé¿©Áú ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 30¾ï 5,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 32¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 48¾ï 3,000¸¸ ´Þ·¯
CAGR(%) 6.77%

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ±â¸éÁõ Àå¾ÖÀÇ À¯º´·ü Áõ°¡
    • ±â¸éÁõ Ä¡·áÁ¦ÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀÇ½Ä Áõ°¡
    • ¼ö¸é °ü·Ã Áúȯ¿¡ ´ëÇÑ ÇコÄɾî ÁöÃâ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±â¸éÁõ Ä¡·áÁ¦ÀÇ ºÎÀÛ¿ë
  • ½ÃÀå ±âȸ
    • ±â¸éÁõ Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê
    • ½Å¾à °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß Ȱµ¿
  • ½ÃÀåÀÇ °úÁ¦
    • ½ÅÈï °æÁ¦ ±¹°¡¿¡ ´ëÇÑ º¸±Þ Áö¿¬

Porter's Five Force : ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ» ³»´Ùº» Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¸íÈ®È÷ÇÏ°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÕ´Ï´Ù. Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

±â¸éÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ±â¸éÁõ Àå¾ÖÀÇ ÀÌȯÀ² Áõ°¡
      • ±â¸éÁõ Ä¡·áÁ¦ÀÇ ÀåÁ¡¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀÇ½Ä Áõ°¡
      • ¼ö¸é °ü·Ã Àå¾Ö¿¡ ´ëÇÑ ÇコÄɾîºñ Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • ±â¸éÁõ Ä¡·áÁ¦ÀÇ ºÎÀÛ¿ë
    • ±âȸ
      • ±â¸éÁõ Ä¡·áÁ¦ °³¹ßÀ» ÇâÇÑ Á¤ºÎÀÇ ´ëó
      • ½Å¾à °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß Ȱµ¿
    • °úÁ¦
      • ½ÅÈï °æÁ¦ ±¹°¡¿¡ ´ëÇÑ Ä§ÅõÀ²ÀÌ ³·´Ù
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå : À¯Çüº°

  • Å»·Â ¹ßÀÛÀ» ¼ö¹ÝÇÏ´Â ±â¸éÁõ
  • Å»·Â ¹ßÀÛÀ» ¼ö¹ÝÇÏÁö ¾Ê´Â ±â¸éÁõ
  • 2Â÷¼º ±â¸éÁõ

Á¦7Àå ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå : Ä¡·áÁ¦ À¯Çüº°

  • ÁßÃß ½Å°æ ÀÚ±ØÁ¦
  • ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö ¾ïÁ¦Á¦
  • ¿Á½Ãº£ÀÌÆ® ³ªÆ®·ý
  • »ïȯ°è Ç׿ì¿ïÁ¦

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Avadel Pharmaceuticals Plc
  • Axsome Therapeutics Inc.
  • Cadila Pharmaceuticals Ltd.
  • Don Valley Pharmaceuticals
  • Graymark Healthcare Inc.
  • Jabs Biotech Pvt. Ltd.
  • Jazz Pharmaceuticals PLC
  • Luckys Pharma Pvt. Ltd.
  • Midas Pharma GmbH
  • Orbion Pharmaceuticals Pvt. Ltd.
  • Shionogi and Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • XWPharma Ltd.
JHS 24.12.20

The Narcolepsy Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.28 billion in 2024, and is projected to grow at a CAGR of 6.77%, to USD 4.83 billion by 2030.

Narcolepsy drugs are targeted treatments for a chronic neurological disorder characterized by an inability to regulate sleep-wake cycles, resulting in excessive daytime sleepiness, cataplexy, and disturbed nocturnal sleep. The necessity for these drugs arises from the growing awareness of narcolepsy's impact on the quality of life, necessitating effective management strategies. Their applications vary, including stimulants for combating daytime lethargy, antidepressants for controlling cataplexy, and sodium oxybate for addressing multiple symptoms. The end-use scope ranges across healthcare settings like hospitals, clinics, and homecare, emphasizing personalized care. Key growth influencers in the narcolepsy drug market include a rise in diagnosed cases, advancements in technology for better drug delivery, and increased healthcare expenditure. There's a push towards developing novel therapies with fewer side effects, opening potential opportunities in personalized medicine and biotech innovations. Continuous regulatory support and integration of artificial intelligence in research for drug development further enhance the market landscape. Challenges hindering growth include the high cost of drugs, potential side effects, limited awareness in underdeveloped regions, and stringent regulatory hurdles that delay the introduction of new therapies. Innovating with non-invasive drug delivery systems, such as transdermal patches, and furthering research into understanding genetic predispositions in narcolepsy are avenues ripe for exploration. Companies should focus on strategic alliances, expansive clinical trials, and robust pricing strategies to enhance affordability. The market is dynamic, necessitating adaptability to rapid scientific advancements and shifts in consumer awareness, requiring stakeholders to remain agile and informed. Addressing limitations through education campaigns and collaboration with regulatory entities can optimize onerous pathways, enhancing product accessibility and fostering broader acceptance. As the market evolves, embracing sustainable practices and digital health integration could provide businesses with actionable insights and a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 3.05 billion
Estimated Year [2024] USD 3.28 billion
Forecast Year [2030] USD 4.83 billion
CAGR (%) 6.77%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Narcolepsy Drugs Market

The Narcolepsy Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of narcolepsy disorder
    • Growing consumer awareness towards benefits of narcolepsy drugs
    • Rising healthcare spending for sleep related disorders
  • Market Restraints
    • Side effects of narcolepsy drugs
  • Market Opportunities
    • Governmental initiatives for narcolepsy drug development
    • Ongoing research and development activities for novel drug development
  • Market Challenges
    • Less penetration across developing economies

Porter's Five Forces: A Strategic Tool for Navigating the Narcolepsy Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Narcolepsy Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Narcolepsy Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Narcolepsy Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Narcolepsy Drugs Market

A detailed market share analysis in the Narcolepsy Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Narcolepsy Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Narcolepsy Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Narcolepsy Drugs Market

A strategic analysis of the Narcolepsy Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Narcolepsy Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma Ltd., Avadel Pharmaceuticals Plc, Axsome Therapeutics Inc., Cadila Pharmaceuticals Ltd., Don Valley Pharmaceuticals, Graymark Healthcare Inc., Jabs Biotech Pvt. Ltd., Jazz Pharmaceuticals PLC, Luckys Pharma Pvt. Ltd., Midas Pharma GmbH, Orbion Pharmaceuticals Pvt. Ltd., Shionogi and Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and XWPharma Ltd..

Market Segmentation & Coverage

This research report categorizes the Narcolepsy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy.
  • Based on Therapeutics Type, market is studied across Central Nervous System Stimulants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate, and Tricyclic Antidepressants.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of narcolepsy disorder
      • 5.1.1.2. Growing consumer awareness towards benefits of narcolepsy drugs
      • 5.1.1.3. Rising healthcare spending for sleep related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects of narcolepsy drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Governmental initiatives for narcolepsy drug development
      • 5.1.3.2. Ongoing research and development activities for novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Less penetration across developing economies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Narcolepsy Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Narcolepsy with Cataplexy
  • 6.3. Narcolepsy without Cataplexy
  • 6.4. Secondary Narcolepsy

7. Narcolepsy Drugs Market, by Therapeutics Type

  • 7.1. Introduction
  • 7.2. Central Nervous System Stimulants
  • 7.3. Selective Serotonin Reuptake Inhibitor
  • 7.4. Sodium Oxybate
  • 7.5. Tricyclic Antidepressants

8. Americas Narcolepsy Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Narcolepsy Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Narcolepsy Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Aurobindo Pharma Ltd.
  • 3. Avadel Pharmaceuticals Plc
  • 4. Axsome Therapeutics Inc.
  • 5. Cadila Pharmaceuticals Ltd.
  • 6. Don Valley Pharmaceuticals
  • 7. Graymark Healthcare Inc.
  • 8. Jabs Biotech Pvt. Ltd.
  • 9. Jazz Pharmaceuticals PLC
  • 10. Luckys Pharma Pvt. Ltd.
  • 11. Midas Pharma GmbH
  • 12. Orbion Pharmaceuticals Pvt. Ltd.
  • 13. Shionogi and Co. Ltd.
  • 14. Takeda Pharmaceutical Co. Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. XWPharma Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦